Can Fite Biopharma Ltd (NYSEAMERICAN:CANF) saw a significant increase in short interest during the month of January. As of January 12th, there was short interest totalling 217,077 shares, an increase of 380.2% from the December 29th total of 45,202 shares. Based on an average trading volume of 261,232 shares, the days-to-cover ratio is presently 0.8 days.
Shares of Can Fite Biopharma (CANF) opened at $2.17 on Tuesday. Can Fite Biopharma has a fifty-two week low of $1.24 and a fifty-two week high of $2.75. The stock has a market capitalization of $34.29, a PE ratio of 6.24 and a beta of 1.79.
Can Fite Biopharma (NYSEAMERICAN:CANF) last released its quarterly earnings results on Monday, November 27th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.09. Can Fite Biopharma had a negative return on equity of 57.94% and a negative net margin of 2,453.03%.
A number of research firms recently commented on CANF. HC Wainwright reiterated a “buy” rating and set a $6.00 price objective on shares of Can Fite Biopharma in a research report on Thursday, February 1st. Maxim Group set a $7.00 price objective on Can Fite Biopharma and gave the company a “buy” rating in a research report on Tuesday, October 17th.
TRADEMARK VIOLATION WARNING: “Can Fite Biopharma Ltd (NYSEAMERICAN:CANF) Short Interest Update” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/02/13/can-fite-biopharma-ltd-canf-short-interest-update.html.
About Can Fite Biopharma
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.
Receive News & Ratings for Can Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.